Alkermes submits Form 10 to SEC for planned separation of oncology business

Alkermes announced that it has submitted a confidential draft Form 10 registration statement to the United States SEC in connection with the previously announced planned separation of the company’s oncology business into an independent, publicly-traded company. The company continues to expect to complete the separation in the second half of 2023. As announced in November 2022, Alkermes’ Board of Directors unanimously approved the exploration of separating the company’s neuroscience business and oncology business. The planned separation is part of a strategic process commenced by the Board to unlock shareholder value through a sharpened strategic focus, simplified capital allocation decision-making, and distinctive investment profiles for each business.